News | October 10, 2025
AstraZeneca to increase investment in Virginia manufacturing facility to $4.5 billion
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Subscribe To Our Newsletter & Stay Updated
